γδ T-cell immunotherapy for lung cancer

Surgery Today

Volumn 41, Issue 5, 2011, Pages 606-611

  Yoshida, Yukihiro ^a   Nakajima, Jun ^a   Wada, Hiromi ^b   Kakimi, Kazuhiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Osaka Wada Clinic   (Japan)

Author keywords

T cells; Immunotherapy; Non small cell lung carcinoma; Prospective study

Indexed keywords

2 METHYL 3 BUTENYL 1 PYROPHOSPHATE; ALENDRONIC ACID; BELAGENPUMATUCEL L; BROMOHYDRIN PYROPHOSPHATE; CANCER VACCINE; HLA A ANTIGEN; HLA B ANTIGEN; IBANDRONIC ACID; INTERLEUKIN 2; L BLP 25; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 3; MEVALONIC ACID; NATURAL KILLER CELL RECEPTOR NKG2D; PAMIDRONIC ACID; PYROPHOSPHORIC ACID DERIVATIVE; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELL THERAPY; CYTOLYSIS; DISEASE FREE SURVIVAL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG FEVER; DRUG RESPONSE; FATIGUE; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INJECTION SITE COLDNESS; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; T LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; DIPHOSPHONATES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 79956212346     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-010-4478-7     Document Type: Review

References (51)

1. Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare of Japan. Vital Statistics of Japan 2008 (in Japanese). Tokyo: Health and Welfare Statistics Association; 2008.
2. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008;3:46-52.
3. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
4. Sugimura H, Nichols FC, Yang P, Allen MS, Cassivi SD, Deschamps C, et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007;83:409-17; discussion 417-8.
5. Ohe Y, Ishizuka N, Tamura T, Sekine I, Nishiwaki Y, Saijo N. Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A). Cancer Sci 2003;94:729-34. (Pubitemid 37160932)
6. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317-23. (Pubitemid 46323100)
7. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
9. Kodama K, Higashiyama M, Takami K, Oda K, Okami J, Maeda J, et al. Innate immune therapy with a Bacillus Calmette-Guerin cell wall skeleton after radical surgery for non-small cell lung cancer: a case-control study. Surg Today 2009;39:194-200.
10. Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, et al. Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008;10:842-56.
11. Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γδ T cells. Eur J Cardiothorac Surg 2010;37:1191-7.
12. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004;350:1461-3. (Pubitemid 38420003)
13. Kakimi K, Nakajima J, Wada H. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer 2009;65:1-8.
14. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, et al. Phase II study of belagenpumatucel-L, a transforming growth factor β-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24:4721-30. (Pubitemid 46630936)
15. Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001;3:49-57; discussion 58.
16. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009;10:371-4.
17. Nemunaitis JJ. Are vaccines making a comeback in non-small-cell lung cancer? J Clin Oncol 2008;26:1402-3.
18. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005;11:8055-62. (Pubitemid 41698748)
19. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
20. Hayday AC. γδ cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000;18:975-1026. (Pubitemid 30365402)
21. Haas W, Pereira P, Tonegawa S. γδ cells. Annu Rev Immunol 1993;11:637-85.
22. Girardi M. Immunosurveillance and immunoregulation by γδ T cells. J Invest Dermatol 2006;126:25-31.
23. Tanaka Y, Sano S, Nieves E, De Libero G, Rosa D, Modlin RL, et al. Nonpeptide ligands for human γδ T cells. Proc Natl Acad Sci USA 1994;91:8175-9.
24. Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature 1995;375:155-8.
25. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-8. (Pubitemid 36152311)
26. Scotet E, Martinez LO, Grant E, Barbaras R, Jeno P, Guiraud M, et al. Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 2005;22:71-80. (Pubitemid 40143452)
27. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007;7:737-44. (Pubitemid 47327391)
28. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96:6879-84. (Pubitemid 29274978)
29. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002;62:6178-86. (Pubitemid 35244469)
30. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 1998;279:1737-40. (Pubitemid 28164472)
31. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-9.
32. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human γδ T Cells. Science 2005;309:264-8. (Pubitemid 40967855)
33. + αβ T cell responses. Proc Natl Acad Sci USA 2009;106:2307-12.
34. Meuter S, Eberl M, Moser B. Prolonged antigen survival and cytosolic export in cross-presenting human γδ T cells. Proc Natl Acad Sci USA 2010;107:8730-5.
35. + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother 1996;5:503-9.
36. Kobayashi H, Tanaka Y, Yagi J, Toma H, Uchiyama T. γδ T cells provide innate immunity against renal cell carcinoma. Cancer Immunol Immunother 2001;50:115-24.
37. Zheng BJ, Chan KW, Im S, Chua D, Sham JS, Tin PC, et al. Antitumor effects of human peripheral γδ T cells in a mouse tumor model. Int J Cancer 2001;92:421-5. (Pubitemid 32249721)
38. Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human Vγ9Vδ2 γδ T cells in vitro and in SCID mice in vivo. J Immunol 2004;173:6767-76. (Pubitemid 39541063)
39. Kunzmann V, Bauer E, Wilhelm M. γδ T-cell stimulation by pamidronate. N Engl J Med 1999;340:737-8.
40. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 2003;102:200-6.
41. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007;67:7450-7.
42. Burjanadze M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C, et al. In vitro expansion of γδ T cells with antimyeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 2007;139:206-16.
43. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using γδ T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007;56:469-76.
44. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-92.
45. Sato K, Kondo M, Sakuta K, Hosoi A, Noji S, Sugiura M, et al. Impact of culture medium on the expansion of T cells for immunotherapy. Cytotherapy 2009;11:936-46.
46. Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous γδ T-cells in a patient with renal cell carcinoma. Anticancer Res 2010;30:575-9.
47. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C, et al. Phase-I study of Innacell γδ, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008;57:1599-609.
48. Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, et al. Clinical and immunological evaluation of zoledronate-activated Vγ9 γδ T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009;37:956-68.
49. + T-cell receptors. J Natl Cancer Inst 1996;88:436-41.
50. Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, Mundhenke C, et al. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human γδ T cells. Cancer Res 2009;69:8710-7.
51. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244-52.